Biogen agreed to acquire RayThera in a deal that could be worth up to $1 billion, gaining a portfolio of early-stage immunology candidates led by programs near the clinic. Details remain limited, but the transaction is structured with an undisclosed upfront payment and potential milestone payments tied to clinical and regulatory progress. The move expands Biogen’s immunology footprint beyond its more established neurology base, following the company’s earlier $5.6 billion purchase of Apellis Pharmaceuticals and its complement-focused assets. RayThera, founded in 2023, has provided sparse pipeline disclosures publicly, but has referenced targets and mechanistic categories consistent with anti-inflammatory exploration. For Biogen, the RayThera acquisition addresses a pipeline-filling need at earlier stages, while for RayThera investors it provides an exit with additional upside tied to milestones. Because the deal was backloaded and milestones-heavy, the economics will likely hinge on RayThera’s first clinical entrants and subsequent data readouts that de-risk target validation and tolerability—key gating factors in immunology development.